Pre-made Praluzatamab benchmark antibody ( Whole mAb, anti-CD166/ALCAM therapeutic antibody, Anti-MEMD Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Praluzatamab biosimilar, Whole mAb, Anti-CD166/ALCAM Antibody: Anti-MEMD therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Praluzatamab Ravtansine is a probody-drug conjugate (PDC) composed of a recombinant antibody targeting the tumor-associated antigen (TAA) CD166, which is masked by a cleavable masking peptide, and conjugated to the cytotoxic agent maytansinoid DM4, with potential antineoplastic activity.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-454-1mg	1mg	3090
GMP-Bios-ab-454-10mg	10mg	Inquiry
GMP-Bios-ab-454-100mg	100mg	Inquiry
GMP-Bios-ab-454-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Praluzatamab biosimilar, Whole mAb, Anti-CD166/ALCAM Antibody: Anti-MEMD therapeutic antibody
INN Name	Praluzatamab
Target	ALCAM
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2019
Year Recommended	2020
Companies	CytomX Therapeutics;Immunogen
Conditions Approved	na
Conditions Active	Solid tumours
Conditions Discontinued	na
Development Tech	na